Stockscreener 앱 받기
33.49
0.15%
0.05
전일 마감가:
$33.44
열려 있는:
$32.59
하루 거래량:
54,504
Relative Volume:
1.02
시가총액:
$131.91M
수익:
$36.84M
순이익/손실:
$-729.00K
주가수익비율:
-36.26
EPS:
-0.9237
순현금흐름:
$-10.02M
1주 성능:
-5.40%
1개월 성능:
+10.02%
6개월 성능:
-5.86%
1년 성능:
+91.37%
1일 변동 폭
$30.49
$33.61
1주일 범위
$30.49
$38.32
52주 변동 폭
$14.00
$44.00
Vtv Therapeutics Inc Stock (VTVT) Company Profile
명칭
Vtv Therapeutics Inc
전화
336-841-0300
주소
3980 PREMIER DR, HIGH POINT, NC
Compare VTVT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
33.49 | 131.91M | 36.84M | -729.00K | -10.02M | -0.9237 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-12 | 개시 | Evercore ISI | Outperform |
| 2026-01-23 | 개시 | Roth Capital | Buy |
| 2026-01-05 | 개시 | TD Cowen | Buy |
| 2025-11-19 | 개시 | BTIG Research | Buy |
| 2019-05-30 | 개시 | H.C. Wainwright | Buy |
| 2018-04-10 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-08 | 개시 | ROTH Capital | Buy |
| 2018-02-08 | 개시 | Northland Capital | Outperform |
| 2016-09-26 | 개시 | H.C. Wainwright | Buy |
| 2015-09-04 | 개시 | Canaccord Genuity | Buy |
| 2015-08-24 | 개시 | Piper Jaffray | Overweight |
| 2015-08-24 | 개시 | Stifel | Buy |
모두보기
Vtv Therapeutics Inc 주식(VTVT)의 최신 뉴스
Technical Reactions to VTVT Trends in Macro Strategies - Stock Traders Daily
MSN Money - MSN
vTv Therapeutics lures two employees with 12,500 stock options - Stock Titan
vTv Therapeutics Shareholders Approve Directors, Question Executive Pay - The Globe and Mail
Trading the Move, Not the Narrative: (VTVT) Edition - Stock Traders Daily
Rodman & Renshaw initiates vTv Therapeutics stock with buy rating By Investing.com - Investing.com Nigeria
Rodman & Renshaw initiates vTv Therapeutics stock with buy rating - Investing.com
Enterprise value to EBITDA forward of vTv Therapeutics Inc. – NASDAQ:VTVT - TradingView
6,000 vTv Therapeutics (VTVT) options granted to director tied to Baker funds - Stock Titan
Form 4 vTv Therapeutics Inc For: 29 June By Investing.com - Investing.com India
[8-K] vTv Therapeutics Inc. Reports Material Event - Stock Titan
vTv Therapeutics (VTVT) director granted 6,000 stock options at $35.08 - Stock Titan
Director at vTv Therapeutics (VTVT) awarded 6,000 stock options grant - Stock Titan
Director at vTv Therapeutics (VTVT) receives 6,000 stock options grant - Stock Titan
Director Fahed Al-Marzooqi (VTVT) granted 6,000 vTv Therapeutics stock options - Stock Titan
Enterprise value to revenue forward of vTv Therapeutics Inc. – NASDAQ:VTVT - TradingView
Price to earnings forward of vTv Therapeutics Inc. – NASDAQ:VTVT - TradingView
Price to book forward of vTv Therapeutics Inc. – NASDAQ:VTVT - TradingView
Price to sales forward of vTv Therapeutics Inc. – NASDAQ:VTVT - TradingView
vTv Therapeutics Q1 2026 Earnings: EPS Surges to $1.94, Driven by Significant SurpriseEPS Miss Report - dars.gov.et
vTv Therapeutics (VTVT) AGM 2026 Summary - Quartr
VTVT: Directors and auditor were approved, but executive compensation was not - TradingView
vTv Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
vTv Therapeutics, Inc. Class A Actuals & Estimates (NASDAQ:VTVT) - TradingView
VTVT Forecast — Price Target — Prediction for 2027 - TradingView
vTv Therapeutics Inc. (VTVT) Q1 2026 Earnings: Massive EPS Surprise Driven by Non-Recurring ItemsEarnings Momentum Score - dars.gov.et
vTv Therapeutics Inc (VTVT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
vTv Therapeutics Inc (VTVT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
(VTVT) Volatility Zones as Tactical Triggers - Stock Traders Daily
vTv Therapeutics Inc. Stock 12‑Month Price Target Raised to $54.8, Implies 56% Upside - TradingView
cAMPfield Launches With $180 Million Series A to Advance Prifemilast, a Potential Best-in-Class Oral Therapy for IBD - Yahoo Finance
vTv Therapeutics Inc (VTVT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
vTv Therapeutics Inc (VTVT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
vTv Therapeutics Inc (VTVT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
vTv Therapeutics Inc (VTVT) Institutional Confidence - TradingKey
vTv Therapeutics Inc (VTVT) Valuation: PE, PB & Fair Value Analysis - TradingKey
vTv Therapeutics Inc (VTVT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
vTv Therapeutics Inc (VTVT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
VTVT Q1 2026 Earnings: Surprise Profit Amid No RevenueEarnings Preview - newsline.com
Price-Driven Insight from (VTVT) for Rule-Based Strategy - Stock Traders Daily
vTv Therapeutics, Inc. Class A Financial Disclosures & SEC Filings - TradingView
VTVT Q1 2026 Earnings: Massive EPS Beat Driven by Non-Operational ItemsForward EPS Estimate - newsline.com
VTVT Technical Analysis | Trend, Signals & Chart Patterns | VTV THERAPEUTICS INC- CL A (NASDAQ:VTVT) - ChartMill
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Stock options, 10-year term: inside vTv Therapeutics grant - Stock Titan
VTVT Stock Price, Quote & Chart | VTV THERAPEUTICS INC- CL A (NASDAQ:VTVT) - ChartMill
vTv Therapeutics Drops as Diabetes Study Date Approaches - Bez Kabli
vTv Therapeutics (VTVT) Edges Lower, Holding Above Key Support Amid ConsolidationRisk Parity Rebalance - thelegaladvocate.com
(VTVT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
vTv Therapeutics Inc. (VTVT) Edges Lower Amid Consolidation Near SupportComposite Profile - dars.gov.et
VTVT Q1 2026 Earnings: Massive EPS Surprise Driven by a Non-Recurring GainEarnings Quality Score - The Legal Advocate
Vtv Therapeutics Inc (VTVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):